Spiro compounds

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Retrieved on: 
Wednesday, June 16, 2021
Organic compounds, Chemical compounds, Chemistry, Pyridines, Spiro compounds, Amines, TRV734, Substance dependence, Opioid use disorder, Opioid, Trevena Inc

The Company has an ongoing collaboration with NIDA to evaluate TRV734 as a potential maintenance therapy for opioid use disorder (OUD).

Key Points: 
  • The Company has an ongoing collaboration with NIDA to evaluate TRV734 as a potential maintenance therapy for opioid use disorder (OUD).
  • Opioid use disorder remains an urgent public health issue even as COVID-19 remains front of mind.
  • The NIDA study of TRV734 marks the third investigational drug product within Trevenas pipeline being researched by the NIH.
  • Trevena is collaborating with NIDA to further evaluate TRV734 as a potential maintenance therapy for opioid use disorder.

Trevena to Release First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Wednesday, May 5, 2021
Organic compounds, Chemical compounds, Branches of biology, Pain, Pyridines, Spiro compounds, Analgesics, Morphine, Opioid, Oliceridine, TRV734, Neuropathic pain

b'The webcast should be accessed 15 minutes prior to the conference call start time.

Key Points: 
  • b'The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the company\xe2\x80\x99s website.\nTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK\xe2\x84\xa2 (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
  • The Company\xe2\x80\x99s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.\n'

Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum

Retrieved on: 
Thursday, April 29, 2021
Organic compounds, Chemical compounds, Pain, Branches of biology, Pyridines, Spiro compounds, Analgesics, Morphine, Opioid, Oliceridine, TRV734, Neuropathic pain

b'Trevena\xe2\x80\x99s panel discussion will be available on demand during the conference to registered participants.\nTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.

Key Points: 
  • b'Trevena\xe2\x80\x99s panel discussion will be available on demand during the conference to registered participants.\nTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK\xe2\x84\xa2 (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
  • The Company\xe2\x80\x99s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.\n'

Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Retrieved on: 
Friday, March 5, 2021
Pyridines, Spiro compounds, Trevena, Oliceridine, Chemistry, Chemical substances

Company to host conference call on March 9th, 2021, at 8:00 a.m.

Key Points: 
  • Company to host conference call on March 9th, 2021, at 8:00 a.m.
  • ET
    CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2020, prior to the market open on Tuesday, March 9th, 2021.
  • The Company will host a conference call and webcast with the investment community at8:00 a.m. ETthat same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Bob Yoder, SVP and Chief Commercial Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.
  • Additionally, Dr. Gregory Hammer, Professor of Anesthesiology, Stanford University Medical Center, will be providing additional remarks on the role of OLINVYK (oliceridine) injection in acute pain management and key considerations in the formulary review process at his institution.

Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Monday, February 22, 2021
Organic compounds, Chemical compounds, Chemistry, Pyridines, Spiro compounds, Amines, TRV734, Opioid, Oliceridine, Analgesic, Medication, Trevena Inc

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.

Key Points: 
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.
  • The Company has one approved product in the U.S., OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
  • The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients.
  • The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

Janssen Announces Treatment with ERLEADA®▼(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Retrieved on: 
Tuesday, February 9, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Chemistry, Prostate cancer, Nonsteroidal antiandrogens, Progonadotropins, Pyridines, Spiro compounds, Apalutamide, the TITAN Study, Metastatic Hormone-Sensitive Prostate Cancer, apalutamide, Janssen Pharmaceutical Companies of Johnson & Johnson

The results of the TITAN final analysis demonstrate that apalutamide with ADT provides a new therapeutic option for people living with advanced, hormone-sensitive prostate cancer.

Key Points: 
  • The results of the TITAN final analysis demonstrate that apalutamide with ADT provides a new therapeutic option for people living with advanced, hormone-sensitive prostate cancer.
  • The results also demonstrate an established safety profile which is encouraging for the management of patients living with advanced forms of prostate cancer.
  • The study included 1,052 patients in 23 countries across 260 sites in North America, Latin America, South America, Europe, and Asia Pacific.
  • Patients with mHSPC were randomised 1:1 and received either apalutamide (240 mg) plus ADT (n=525), or placebo plus ADT (n=527).

Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

Retrieved on: 
Monday, January 11, 2021
Alternative medicine, Health, Research, Pharmaceutical, Science, Biotechnology, Organic compounds, Life sciences, Biotechnology, Biology, Spiro compounds, Plant toxins, Secondary alcohols, Biological engineering, Cyclopamine, Cryopreservation, Cell culture, Bioreactor, Phyton Biotech, PellePharm, Patidegib

Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharms patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions.

Key Points: 
  • Phyton Biotech today announced that it has established high-yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharms patedigib topical gel, an investigational treatment to be used for rare dermatologic conditions.
  • Through Phytons proprietary Plant Cell Fermentation (PCF) technology, researchers successfully developed high-yielding plant cell lines of V. californicum and established protocols for cryopreservation, allowing for stable long-term storage of cell lines in liquid nitrogen.
  • In addition, Phyton Biotech demonstrated its ability to express cyclopamine directly from V. californicum plant cell cultures via PCF and also showed that cyclopamine can be expressed efficiently in a standard bioreactor environment.
  • Further development and full scale-up to a commercially viable process is anticipated in the next project phase.

Decipher Biosciences Announces its Genomic Data Featured at 2019 Genitourinary Conference in Multiple Prostate Cancer Presentations

Retrieved on: 
Thursday, February 14, 2019
Chemistry, Organic chemistry, Cancer, Prostate cancer, Benzamides, Nonsteroidal antiandrogens, Pyridines, Spiro compounds, Apalutamide, Oncology

Title: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.

Key Points: 
  • Title: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
  • Abstract #8
    Title: Genomic validation of three-tiered sub-classification of high-risk prostate cancer.
  • Abstract #44
    Presenter:Amar Upadhyaya Kishan, MD, Ronald Reagan UCLA Medical Center, Santa Monica, CA
    Title: Do elderly men (>75) harbor more aggressive prostate cancer?
  • Decipher Biosciences' prostate and bladder cancer classifiers are clinical, commercially available oncology tests that provide a genomic assessment of tumor aggressiveness for individual patients.

Phyton Biotech Partners with PellePharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy

Retrieved on: 
Thursday, January 31, 2019
Health, Biotechnology, Organic compounds, Health sciences, Pharmacology, Alcohols, Spiro compounds, Cyclopamine, Teratogens, Breakthrough therapy, Gorlin, Topical medication, Phyton

Under its agreement with PellePharm, Phyton Biotech will begin development of the new process immediately.

Key Points: 
  • Under its agreement with PellePharm, Phyton Biotech will begin development of the new process immediately.
  • We are incredibly excited to partner with PellePharm as pioneers in precision medicine to advance this topical skin cancer treatment to the next level of excellence with our patented PCF technology, said Colin Marr, president of Phyton Biotech.
  • The partnership with PellePharm follows Phyton Biotechs successful demonstration of its ability to express cyclopamine directly from Veratrum californicumplant cell cultures via PCF.
  • PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for patidegib topical gel in Gorlin Syndrome from the U.S. Food and Drug Administration (FDA).

Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Wednesday, July 4, 2018
Chemistry, Prostate cancer, Organic chemistry, Cancer, Pyridines, Benzamides, Nonsteroidal antiandrogens, Spiro compounds, Apalutamide, Prostate, Management of prostate cancer, Abiraterone acetate

"Until now, men living with this stage of prostate cancer have been forced to wait for their condition to worsen in order to be eligible for the next therapy," said Dr. Stuart Edmonds, Vice President, Research, Health Promotion and Survivorship, Prostate Cancer Canada.

Key Points: 
  • "Until now, men living with this stage of prostate cancer have been forced to wait for their condition to worsen in order to be eligible for the next therapy," said Dr. Stuart Edmonds, Vice President, Research, Health Promotion and Survivorship, Prostate Cancer Canada.
  • This was a first-time collaboration between the two health regulators for the evaluation of a new chemical entity.
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer.
  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.